In CKD, SGLT2i reduced HF hospitalization when compared to incretin-based therapies (HR 0.72, 95% CI 0.58–0.90), with no significant difference when compared to finerenone (HR 0.84, 95% CI 0.67–1.07) or between incretin-based therapies and finerenone (HR 1.17, 95% CI 0.88–1.56). The gene discussed is GCG; the disease is hydrops fetalis.